Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 1 1

Status

Terminated 1Active not recruiting 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Sarcoma 1Gynecologic 1

Conditions

Endometrial Neoplasms 1Bone Neoplasms 1

Interventions

Cyclophosphamide 910Carboplatin 788pembrolizumab 747Paclitaxel 744Bevacizumab 716Cisplatin 709Gemcitabine 621Docetaxel 584Rituximab 558Radiotherapy 548Dexamethasone 511Nivolumab 491Doxorubicin 445Fluorouracil 392Capecitabine 382Etoposide 358Pemetrexed 339Cytarabine 335Oxaliplatin 335Lenalidomide 328Prednisone 327Erlotinib Hydrochloride 323fludarabine phosphate 316Trastuzumab 305Leucovorin 299fludarabine 296Vincristine 288Bortezomib 284Filgrastim 284Cetuximab 277

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Has results × Sodium Pertechnetate Tc 99m × Clear all
NCT03120624 2026-02-04

VSV-hIFNbeta-NIS With or Without Ruxolitinib Phosphate in Treating Stage IV or Recurrent Endometrial Cancer

Mayo Clinic

Phase 1 Active not recruiting
34 enrolled 16 charts
Gynecologic

Endometrial Neoplasms

NCT03002454 2017-10-03

Sodium Pertechnetate (99Tc) Injection Generator: 99mTc From Neutron-activation 99Mo v 99mTc From Fission 99Mo

University of Manitoba

Phase 3 Terminated
4 enrolled 5 charts
Sarcoma

Bone Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡